65,437 trials
Hypoxemia
Primary: Detection of Oxygen Alarms That Resulted in Clinicians Changing the Care of the Infant. — 39.9; 44.4; 48.0; 50.3 percentage of interventions
Psoriatic Arthritis
Primary: Number of Participants With an American College of Rheumatology (ACR) 20 Response at Week 12 — 10; 32 Participants — p=<0.001
Spinal Cord Injuries
Primary: Discomfort Measured on a VAS Scale 0 Being no Discomfort, 10 Being Worst Imaginable Discomfort. — 1.59; 1.94 units on a scale
Rheumatoid Arthritis
Primary: The Number of Participants Achieving Remission As Measured by a Disease Activity Score for 28 Joints (DAS 28) < 2.6. — 73; 132 participants — p=<0.001
Glaucoma, Open-Angle · Ocular Hypertension
Primary: Percentage of Patients With a Reduction in Intraocular Pressure (IOP) ≥ 5mmHg From Baseline — 75.9 Millimeters of Mercury (mmHg)
Type 2 Diabetes Mellitus
Primary: Area Under the Curve (AUC)(0-∞) for Oral Compressed Tablet (OCT) (Fasted) and Dry Filled Capsule (DFC) (Fasted) — 763.76; 776.41 nM*hr — p=>0.200
Influenza
Primary: Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) — 0; 0; 0; 0 subjects
Muscle Damage · Muscle Inflammation
Primary: Quadriceps Muscle Strength — 151; 160 lbs — p=>0.05
Fibrillation, Atrial
Primary: Number of Participants With at Least One Event of Cerebral Neurologic Event, Systemic Thromboembolism, Death From Any Cause, and/or Major Bleeding Until the End of…
Lower Urinary Tract Symptoms · Bladder Outlet Obstruction
Primary: Change From Baseline to End of Treatment in Maximum Flow Rate (Qmax) — -0.33; 0.07; 0.30 mL/sec
Smoking Cessation
Primary: Number of Participants With Prolonged Abstinence Through 6 Months Verified by Carbon Monoxide Measurement — 12; 20; 7 participants — p=0.30
Attention Deficit Disorder With Hyperactivity
Primary: Dupaul ADHD Rating Scale — 31.4; 13.6 units on a scale
Gastroesophageal Reflux
Primary: Change From Baseline in Reflux Disease Symptom - Heartburn — 59; 117; 186; 7 participants
Cancer
Primary: Number of Participants Who Had Reactogenicity Events (REs) — 8; 9 participants
Hyperuricemia
Primary: Number of Patients With Acute Kidney Injury (AKI). — 13; 13 Participants